enabling the initiation of a Phase 3 study. This single registrational study, identified as ICoN-1, is likely to commence in the U.S. by the end of the second quarter of 2024, and internationally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback